Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $1126
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Regeneron Pharmaceuticals but has lowered the price target from $1137 to $1126.
November 01, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has maintained a Buy rating on Regeneron Pharmaceuticals but has lowered the price target from $1137 to $1126.
The maintenance of a Buy rating suggests continued confidence in Regeneron's performance, but the lowered price target indicates a slight reduction in expected upside. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100